Comparative efficacy of pegylated interferons α-2a and 2b in the treatment of HBeAg-negative chronic Hepatitis B infection

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 11, 2012, Pages 1296-1301

  Karabay, Oguz ^a   Tuna, Nazan ^a   Esen, Şaban ^b  

^a SAKARYA UNIVERSITY   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Chronic hepatitis B; Pegylated interferon; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LIVER ENZYME; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; THYROTROPIN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEALTH CARE FACILITY; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; TURKEY (REPUBLIC);

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TURKEY; VIRAL LOAD;

EID: 84867329973     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328356eac2     Document Type: Article

References (37)

1. Chien R-N. Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B. Hepatol Int 2008; 2: 296-303.
2. Huang L-M, Lu C-Y, Chen D-S. Hepatitis B virus infection, its sequelae, and prevention by vaccination. Curr Opin Immunol 2011; 23:237-243.
3. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007; 11:797-816. (Pubitemid 350019025)
4. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008; 8:167-178. (Pubitemid 351249242)
5. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction oftreatment-related HBsAg loss in HBe negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther2007; 12:73-82. (Pubitemid 46340428)
6. Hadziyannis SJ,Vassilopoulos D. Hepatitis Be antigen-negative chronic hepatitis B. Hepatology 2001; 34:617-624.
7. Chu CJ, Hussain M, LokAS. Quantitative serum HBVDNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36:1408-1415. (Pubitemid 35407438)
8. Ribeiro RM, Germanidis G, Powers KA, Pellegrin B, Nikolaidis P, Perelson AS, Pawlotsky JM. Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J Infect Dis 2010; 202:1309-131 8.
9. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003; 38:1075-1086. (Pubitemid 37314815)
10. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215-229. (Pubitemid 40364823)
11. García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, et al. Pharmacokinetic and pharmacodynamic comparison of two 'pegylated' interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover,double-blind study. BMCPharmacol2010; 10:15.
12. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8:275-284.
13. Lau GKK, Piratvisuth T, Luo KX, Marcellin P,Thongsawat S, Cooksley G, etal. Peginterferon alpha-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
14. Pawlotsky J, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134:405-415. (Pubitemid 351181309)
15. Lampertico P,Viganò M, Colombo M. Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon. Liver Int 2011; 31 (Suppl 1):90-94.
16. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26 (Suppl 1):123-130.
17. Leblebicioglu H, Eroglu C. Members of the Hepatitis Study Group. Acute hepatitis B virus infection in Turkey: epidemiology and genotype distribution. Clin Microbiol Infect 2004; 10:537-541. (Pubitemid 38961579)
18. EASL Clinical. Practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
19. Mangia A, Antonucci F, Brunetto M, Capobianchi M, Fagiuoli S, Guido M, et al.; Italian Association for the Study of the Liver (AISF). The use of molecular assays in the management of viral hepatitis. Dig Liver Dis 2008; 40:395-404.
20. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435. (Pubitemid 12218164)
21. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9:52-61. (Pubitemid 36002487)
22. Karaaslan H, Yurdaydin C. Viral hepatitis at the blacksea region: the problem of viral hepatitis in turkey revisited. Turk J Gastroenterol 2009; 20:1-2.
23. Cooksley WGE, Piratvisuth R, Lee S-D, Mahachai V, Chao YC, TanWandee T, etal. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatitis 2003; 10:298-305. (Pubitemid 36801917)
24. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alpha-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217. (Pubitemid 39296307)
25. Kaymakoglu S, Danalioglu A, Demir K, Karaca C, Akyuz F, Onel D, et al. Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B. Dig Dis Sci 2007; 52:727-731.
26. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. HBV 99-01 Study Group. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297-303. (Pubitemid 43381671)
27. Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Lau GKK, Farci P, etal. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a±lamivudine: results of 5-year post-treatment follow up. J Hepatol 2009; 50:S336.
28. Bozdayi AM, Aslan N, Bozdayi G, Turkyilmaz AR, Sengezer T, Wend U, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol2004; 149:2115-2129. (Pubitemid 39508954)
29. Ozdemir FT, Duman D, Ertem D, Avsar E, Eren F, Ozdogan O, et al. Determination of hepatitis B genotypes in patients with chronic hepatitis B virus infection in Turkey. Turk J Gastroenterol 2005; 16:183-187. (Pubitemid 43266364)
30. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998-1002.
31. Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 2010; 52:441-449.
32. Lampertico P, Del NE, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37:756-763. (Pubitemid 36397385)
33. Asselah T, Lada O, Moucari R, Martinot M, Boyer N, Marcellin P. Interferon therapy for chronic hepatitis B. Clin Liver Dis 2007; 11:839-849. (Pubitemid 350027767)
34. Senturk H, Baysal B, Tahan V, Zerdali H, Ozaras R, Tabak F, et al. Long-term effect of interferon therapy in patients with HBeAg positive chronic hepatitis B infection. Dig Dis Sci 2011; 56:208-212.
35. Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, et al. Response to interferon alpha is hepatitis B genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-1013. (Pubitemid 40873918)
36. Erhardt A, Ludwig AD, Brunetto M, van Boemmel F, Wolf E, Goebel T, et al. HBV genotypes are the strongest predictors of response to interferon alpha treatment: multivariate evaluation in 1229 hepatitis B patients. Hepatology 2008; 48(Suppl):700A.
37. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49 (5 Suppl):S103-S111.